Iterum Therapeutics plc (ITRM)

NASDAQ: ITRM · Real-Time Price · USD

0.6518

-0.0182 (-2.72%)

At close: Nov 3, 2025, 4:00 PM EST

0.6596

+0.0078 (1.20%)

Pre-market: Nov 4, 2025, 8:13 AM EST

Iterum Therapeutics Employees

Iterum Therapeutics had 9 employees as of December 31, 2024. The number of employees decreased by 5 or -35.71% compared to the previous year.

Employees

9

Change (1Y)

-5

Growth (1Y)

-35.71%

Revenue / Employee

n/a

Profits / Employee

-$2,675,111

Market Cap

29.11M

Employees Chart

Employees History

Date	Employees	Change	Growth
Dec 31, 2024	9	-5	-35.71%
Dec 31, 2023	14	0	-
Dec 31, 2022	14	1	7.69%
Dec 31, 2021	13	6	85.71%
Dec 31, 2020	7	-37	-84.09%
Dec 31, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Dec 31, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro

Related Stocks

Company Name	Employees
UnitedHealth Group	400,000
Johnson & Johnson	138,100
Thermo Fisher Scientific	125,000
Abbott Laboratories	114,000
AstraZeneca	92,900
Novo Nordisk	77,349
Novartis AG	75,883
Merck & Co.	75,000

Employee Rankings

ITRM News

21 days ago - Iterum Therapeutics to Present Data at IDWeek 2025 - GlobeNewsWire
6 weeks ago - Iterum Therapeutics Provides Business Update - GlobeNewsWire
2 months ago - Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S. - GlobeNewsWire
3 months ago - Iterum Therapeutics plc (ITRM) Q2 2025 Earnings Call Transcript - Seeking Alpha
3 months ago - Iterum Therapeutics Reports Second Quarter 2025 Financial Results - GlobeNewsWire
3 months ago - Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 - GlobeNewsWire
4 months ago - Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
4 months ago - Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth - GlobeNewsWire